A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

NCT04963296 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

303

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Obinutuzumab
DRUG: Placebo
DRUG: Acetaminophen/Paracetamol
DRUG: Diphenhydramine hydrochloride
DRUG: Methylprednisolone

Sponsor

Hoffmann-La Roche